Fungal keratitis
Conditions
Interventions
Fungal keratitis group:No intervention required
Control group:No intervention required
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Clinical Diagnosis: Clinically diagnosed with fungal keratitis of severe severity, where drug therapy is assessed as ineffective or unsuitable. Degree of Corneal Lesion: Presence of impending perforation, existing perforation, or extensive corneal thinning with ulcers extending to the stromal layer, where conservative treatment fails to control infection or disease progression. Age Range: Typically 18–75 years old (specific range adjusted per study design), with full legal capacity. Informed Consent: The patient or their legal representative fully understands the nature, purpose, procedures, potential risks, and benefits of the study and voluntarily signs a written informed consent form. Laboratory Criteria: Baseline hematology, liver and kidney function, and other basic test results are within acceptable ranges, or the investigator determines they do not compromise surgical safety or study assessment.
Exclusion criteria
Exclusion criteria: Incompatible infection type: Pathological examination (e.g., smear, culture) confirms or strongly suggests simple bacterial, viral (e.g., herpes simplex virus), amoebic, or mixed keratitis (predominantly non-fungal). Endophthalmitis has spread to the posterior segment (vitreous, retina). Contralateral eye condition: The contralateral eye has extremely poor vision (e.g., light perception or no light perception), making the study eye the patient's sole functional eye (unless emergency eye salvage surgery is required). Severe systemic diseases: Uncontrolled systemic infections or immunodeficiency disorders (e.g., uncontrolled AIDS). Uncontrolled diabetes, hypertension, severe cardiovascular or cerebrovascular disease, liver or kidney failure, etc., which increase surgical and anesthetic risks. Active autoimmune diseases or long-term use of high-dose immunosuppressive agents (excluding post-operative medications permitted by the study). Other severe ocular pathologies: severe eyelid deformities, incomplete closure, active infections of the lacrimal system. Uncontrolled glaucoma. Severe ocular surface diseases such as Stevens-Johnson syndrome or extensive scarring following chemical burns. Severe structural damage to the eyeball precluding corneal transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Corneal thickness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Organ inflammatory response and tissue damage; | — |
Countries
China
Contacts
Public ContactGuangying Zheng
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed